Last reviewed · How we verify
NCT06917495
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
Phase 2 trial testing Rifampin in Mild Spinal Tuberculosis in 300 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Shandong University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 5 April 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rifampin — full drug profile →
- Isoniazid (ISONIAZID) — full drug profile →
- Rifapentine (RPT)
- Moxifloxacin (moxifloxacin) — full drug profile →
- Pyrazinamide (PYRAZINAMIDE) — full drug profile →
- Ethambutol (ETHAMBUTOL) — full drug profile →
Conditions studied
- Mild Spinal Tuberculosis — all drugs for Mild Spinal Tuberculosis →
Sponsor
Shandong University
Who can join
12 and older, any sex, with Mild Spinal Tuberculosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rifapentine- and moxifloxacin-containing short-course regimens for mild spinal tuberculosis: study protocol for a multicenter, randomized, non-inferiority phase II clinical trial.
Wu YE, Cao J, Wang L, Wei YJ, et al · · 2025 · PMID 41487489 · DOI 10.3389/fphar.2025.1684771
Verify or expand the search:
- PubMed search for NCT06917495
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rifampin
Trials testing the same drug.
- NCT07357610 — An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healt · Phase 1 · recruiting
- NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
- NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
- NCT06701136 — Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults · Phase 1 · not yet recruiting
- NCT06835465 — A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants · Phase 1 · completed
Other Shandong University trials
Trials by the same sponsor.
- NCT07288346 — Effect of Predictive Model on Double-Balloon Enteroscopy · NA · recruiting
- NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
- NCT07319312 — Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania · recruiting
- NCT07391787 — Low-acid Contrast Media for Preventing Post ERCP Pancreatitis · completed
- NCT07066059 — Study on the Efficacy and Safety of Shouhui Tongbian Capsules in Protecting Intestine During the Perioperative Period · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06917495 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong University
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06917495.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing